Latest revenue
$4.9M
as of 2025-09-30
Latest net income
$-55.8M
as of 2025-09-30
Net margin
-1127.1%
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ACLX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.73B
- Enterprise value
- $6.65B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 16.72×
- Dividend yield
- 0.0%
- 52-wk high
- $115.13
- 52-wk low
- $60.35
- Beta
- —
- Shares out
- 58.5M
5-year trend
What this company does
Arcellx is a clinical-stage biotech developing CAR-T cell immunotherapies built on its proprietary D-Domain binding scaffold to treat blood cancers, solid tumors, and autoimmune diseases. The company generates no product revenue yet and funds itself primarily through its co-development and co-commercialization collaboration with Gilead's Kite Pharma on lead candidate anito-cel for multiple myeloma. Gilead agreed to acquire Arcellx in February 2026, just two months after Arcellx filed its first BLA for anito-cel, which has an FDA decision date of December 23, 2026.
Generated from ACLX's filing dated 2026-02-26
Key risks
- Pending Gilead merger (announced Feb 22, 2026) caps upside; deal-break risk if antitrust, BLA delays, or shareholder issues derail closing.
- Pipeline concentration: anito-cel drives valuation; PDUFA date December 23, 2026 means any FDA delay or CRL is highly material.
- Kite dependency: Gilead/Kite controls anito-cel manufacturing, Phase 3 iMMagine-3, and co-commercialization, limiting Arcellx's operational and economic control.
Generated from ACLX's filing dated 2026-02-26
Profitability
Operating margin
-1135.6%
791.0%Net margin
-1027.3%
932.9%Return on equity
-56.9%
157.3%Return on assets
-37.9%
151.2%Leverage
Debt / equity
0.50×
7.7%Long-term debt / equity
0.10×
Debt / assets
33.4%
5.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $1.7M | -89.2% | $-58.1M | -23.4% | -3513.4% |
Q3 2025 2025-09-30 | $4.9M | -81.0% | $-55.8M | -115.6% | -1127.1% |
Q2 2025 2025-06-30 | $7.6M | -72.4% | $-52.8M | -94.0% | -698.6% |
Q1 2025 2025-03-31 | $8.1M | -79.3% | $-62.3M | -765.1% | -766.0% |
Q4 2024 2024-12-31 | $15.3M | — | $-47.1M | — | -308.4% |
Q3 2024 2024-09-30 | $26.0M | +74.0% | $-25.9M | +34.2% | -99.4% |
Q2 2024 2024-06-30 | $27.4M | +91.5% | $-27.2M | -14.0% | -99.3% |
Q1 2024 2024-03-31 | $39.3M | — | $-7.2M | — | -18.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ACLX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$18.7M
Net activity
−$18.7M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACLX
Institutional value
$2.24B
Total shares held
19.7M
Distinct holders
121
-96 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 6.7M | $771.7M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 3.9M | $453.0M | +396.5K (+11.2%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $278.5M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $278.4M | — | New |
| 5 | JPMORGAN CHASE & CO | 593.6K | $68.1M | -860.9K (-59.2%) | Trimmed |
| 6 | Magnetar Financial LLC | 394.9K | $45.3M | — | New |
| 7 | ALPINE ASSOCIATES MANAGEMENT INC. | 378.0K | $43.4M | — | New |
| 8 | VANGUARD FIDUCIARY TRUST CO | 308.5K | $35.4M | — | New |
| 9 | AJU IB Investment Co., Ltd. | 223.5K | $25.7M | +0 (+0.0%) | No change |
| 10 | UBS Group AG | 194.7K | $22.4M | -121.9K (-38.5%) | Trimmed |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 151.6K | $17.4M | +148.0K (+4104.1%) | Added |
| 12 | Bank of New York Mellon Corp | 143.1K | $16.4M | +19.9K (+16.2%) | Added |
| 13 | CREDIT INDUSTRIEL ET COMMERCIAL | 134.6K | $15.5M | — | New |
| 14 | GARDNER LEWIS ASSET MANAGEMENT L P | 123.2K | $14.1M | — | New |
| 15 | Hudson Bay Capital Management LP | 122.9K | $14.1M | -278.0K (-69.3%) | Trimmed |
| 16 | PICTON MAHONEY ASSET MANAGEMENT | 120.0K | $13.8M | — | New |
| 17 | CIBRA Capital Ltd | 88.6K | $10.2M | — | New |
| 18 | Nuveen, LLC | 85.3K | $9.8M | +3.4K (+4.1%) | Added |
| 19 | DEUTSCHE BANK AG\ | 80.7K | $9.3M | -152.9K (-65.5%) | Trimmed |
| 20 | Chicago Capital Management, LLC | 93.0K | $8.0M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With Gilead's Merger Agreement signed February 22, what specific go-shop provisions, termination fees, or competing bid protections did Arcellx accept?
- 2
Given iMMagine-1's 24-month PFS dropped to 62% from 93% at 6 months, does durability still support 'best-in-class' positioning versus Carvykti?
- 3
What contingencies around the December 23, 2026 PDUFA date or CRL risk could trigger Gilead's walk-away rights under the merger?
Refreshed when ACLX files a new report · last from 2026-02-26
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.